Our expertise ranges across many industries, products and technologies but our focus is foremost on the emerging Cannabinoid research and product markets. This exciting market is already worth £300m in the UK alone and is expected to be £1bn by 2025. Globally the market is expected to continue to grow at over 30% per annum from its current value of £8bn.
Our most recent experience in the non-tobacco nicotine business, which shows many of the same characteristics as the Cannabinoid market, still offers great opportunities despite being increasingly dominated by the tobacco industry. As the tobacco companies continue to shift their approach to innovation more towards that of the open approach of the pharmaceutical industries they are looking for new opportunities to invest in.
Our focus is on maximising shareholder value by ensuring you do the right thing and to try to stop you doing the wrong thing. In emerging markets there are many great ideas, but not all are commercially viable, and each carries its own intrinsic risk. Our objective is to ensure you have the right strategy and the right team to deliver the returns you expect from your investment while cognoscente of your appetite for risk.
This advice will consider multiple factors including market insights, the core science & technology, the resources and risks associated with scaling the business, the skills of the existing management, shareholder motivations, and market factors.